ClinicalTrials.gg
WithdrawnNCT03155828Updated Aug 3, 2018

Using CPAP to Improve Menstruation in Women With Polycystic Ovarian Syndrome and Obstructive Sleep Apnea

An observational study in Sleep Apnea, Obstructive, Anovulation and Polycystic Ovarian Syndrome, sponsored by University of Louisville. Withdrawn at 1 site in United States. Open to female participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2018-08-03.

Sponsored by University of Louisville · Observational

Why this study was withdrawn
Lack of enrollment
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
0
Ages
18 Years to 35 Years
Sex
Female
01

Study summary

The purpose of this study is to determine if treatment of obstructive sleep apnea (OSA) with continuous positive airway pressure in women with both OSA and polycystic ovarian syndrome will improve the regularity of the women's menstrual cycles.

Read the detailed description

Women seeking fertility treatment at the University of Louisville will be screened for polycystic ovarian syndrome (PCOS) based on history and then blood work if history suggests PCOS. After establishing a diagnosis of PCOS based on the National Institute of Health criteria, they will be screened for impaired glucose tolerance, Class III obesity, and obstructive sleep apnea [using the Epworth Sleepiness Scale (ESS) as the initial screen]. For those women that screen positive on the ESS, they will be referred to the University of Louisville Physicians Sleep Center for a formal sleep study. Only patients with PCOS, severe obstructive sleep apnea, impaired glucose tolerance, and Class III obesity will qualify for enrollment in the study. Once enrolled, patients will be encouraged to use continuous positive airway pressure (CPAP, standard of care for treatment of obstructive sleep apnea) for at least six months. During those six months, patients will be asked to track their menstrual cycles and whether they took progesterone to induce a withdrawal bleed during that time period. The use of ovulation predictor kits to help determine ovulation status will be encouraged, but not required for the study.

During initial evaluation, patients seeking fertility care having a clinical presentation concerning for PCOS have their blood drawn for evaluation of thyroid stimulating hormone, free and total testosterone, antimullerian hormone, and 2 hour glucose tolerance test. At the conclusion of six months of CPAP therapy, patients will be asked to repeat the above blood tests for comparison to baseline values.

Women can continue to attempt pregnancy during the study time period if they desire.

02

Conditions studied

  • Sleep Apnea, Obstructive
  • Anovulation
  • Polycystic Ovarian Syndrome

Keywords

  • PCOS, OSA, CPAP
03

In context

Sleep Apnea, Obstructive

2,240 studies on the registry are indexed under Sleep Apnea, Obstructive; 475 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Lead sponsor

University of Louisville is the lead sponsor of 291 studies on the registry; 54 are open to participants now.

Of its 19 completed or terminated interventional studies of FDA-regulated products, 7 (37%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Women seeking fertility treatment at the University of Louisville Reproductive Endocrinology and Infertility Center who have diagnosed polycystic ovarian syndrome, glucose intolerance, obesity, and obstructive sleep apnea.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-35
  • English speakers
  • Polycystic ovarian syndrome by NIH criteria
  • Abnormal 2 hour glucose tolerance test
  • >/= 40 kg/m2
  • Severe obstructive sleep apnea diagnosed with either a home or in-house sleep study

Exclusion criteria

Exclusion Criteria:

  • Age \<18 or >35
  • Non English speakers
  • No diagnosis of PCOS
  • Normal glucose tolerance test
  • No diagnosis of obstructive sleep apnea
  • \< 40 kg/m2
  • Using any form of hormonal
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
0 participants (actual)
Patient registry
No

Interventions

  • DeviceCPAP

    Women with diagnosed obstructive sleep apnea will be treated using continuous positive airway pressure as per standard of care.

06

What researchers measure

Primary outcomes

  1. Menstrual Cyclicity

    Resumption of regular cycles as evaluated either by paper menstrual calendar or use of a menstrual cycle application on smart phone or tablet.

    Time frame: 6 months

Secondary outcomes

  1. Ovulation

    Resumption of ovulatory cycles as evaluated by positive ovulation predictor kits.

    Time frame: 6 months

07

Study locations

1 site
  • University of Louisville Fertility Center
    Louisville, Kentucky 40205, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2016 to primary completion in Aug 2018, 25 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2017
First posted
May 16, 2017
StartActual
Jul 2016
Primary completionActual
Aug 1, 2018
CompletionActual
Aug 1, 2018
Last update
Aug 3, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03155828
Responsible party
Kelly Pagidas (Professor, Obstetrics and Gynecology and Women's Health, University of Louisville) — Principal investigator
First posted
May 16, 2017
Start date
Jul 2016
Primary completion
Aug 1, 2018
Completion
Aug 1, 2018
Last update
Aug 3, 2018

Study contacts

Kelly Pagidas, MD
principal investigator · University of Louisville

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion